Top Back to top

Trends in allogeneic stem cell transplantation (HSCT) over two decades in patients with secondary acute myelogenous leukemia (sAML) being transplanted from sibling (MSD) or unrelated donors (UD). A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Acute Leukemia Working Party (ALWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Acute Myeloid Leukaemia (AML)
Short title:
Trends in allo for sec AML
Primary objective:
This study is a retrospective registry-based analysis to study trends in HSCT outcome over two decades (2011-2020 vs 2000-2010) in patients with sAML undergoing transplantation from sibling or unrelated donors.
Key inclusion criteria:
• sAML including therapy related AML (tAML)
• adults, age ≥ 18 years
• Transplant dates 2011-2020 vs 2000-2010
• HLA matched sibling or 9-10/10 unrelated donors
• PBSC or bone-marrow as the stem cell source
• CR1
• Myeloablative (MAC) or Reduced- intensity conditioning
• All cytogenetics risk
Principal investigator:
Arnon Nagler